[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLyDvvIEC1xeTuvCeTH6usC6TSba3z1FpHfMhx3i0tmo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Maisonneuve-Rosemont Hospital",[4],73,false,2,1,8153,0,46,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Pain",5,{"name":18,"count":19},"Healthy",3,{"name":21,"count":19},"Anesthesia",{"name":23,"count":8},"Glaucoma, Open-Angle",{"name":25,"count":8},"Breast Cancer",{"name":27,"count":8},"Complex Regional Pain Syndromes",{"name":29,"count":9},"Electromagnetic Interference",{"name":31,"count":9},"Glaucoma",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,81,106,131,157,185,203,229,251,276,304,322,355,373,391,409,433,461,479,497,515,538,564,587,613,637,678,700,737,762,789,814,838,856],{"intervention":42,"totalTrials":8,"cells":43},"Dexmedetomidine",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":52,"NA":79},{"trials":45,"activeCount":11},[],{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[54,67],{"nctId":55,"briefTitle":56,"status":57,"phases":58,"primaryCompletion":59,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":66},"NCT01791296","Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?","COMPLETED",[38],"2016-06","2016-12","2011-01",100,[64,65],"Sleep Deprivation","Delirium",[42],{"nctId":68,"briefTitle":69,"status":70,"phases":71,"primaryCompletion":72,"completion":72,"start":73,"enrollment":74,"conditions":75,"interventions":77},"NCT01381627","Safety Evaluation of Dexmedetomidine for EBUS-TBNA","UNKNOWN",[38],"2013-06","2011-06",60,[76],"Lung Cancer",[78,42],"Remifentanil",{"trials":80,"activeCount":11},[],{"intervention":82,"totalTrials":9,"cells":83},"topical prostaglandin analogs",{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":104},{"trials":85,"activeCount":11},[],{"trials":87,"activeCount":11},[],{"trials":89,"activeCount":11},[],{"trials":91,"activeCount":11},[],{"trials":93,"activeCount":11},[94],{"nctId":95,"briefTitle":96,"status":57,"phases":97,"primaryCompletion":98,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":103},"NCT02388360","The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma",[38],"2016-06-30","2016-11-16","2013-05-06",35,[23],[82],{"trials":105,"activeCount":11},[],{"intervention":107,"totalTrials":9,"cells":108},"Aflibercept",{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":129},{"trials":110,"activeCount":11},[],{"trials":112,"activeCount":11},[],{"trials":114,"activeCount":11},[],{"trials":116,"activeCount":11},[],{"trials":118,"activeCount":11},[119],{"nctId":120,"briefTitle":121,"status":70,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"NCT02924987","Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema",[38],"2017-11","2016-11",40,[127],"Diabetic Macular Edema",[107],{"trials":130,"activeCount":11},[],{"intervention":132,"totalTrials":9,"cells":133},"Dorzolamide 20 mg and Timolol 5 mg",{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":155},{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[144],{"nctId":145,"briefTitle":146,"status":57,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT00957190","The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)",[38],"2011-09-14","2012-02","2009-05-04",25,[153],"Eye Disease",[132],{"trials":156,"activeCount":11},[],{"intervention":158,"totalTrials":9,"cells":159},"Sodium polystyrene sulfonate",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":183},{"trials":161,"activeCount":11},[],{"trials":163,"activeCount":11},[],{"trials":165,"activeCount":11},[],{"trials":167,"activeCount":11},[],{"trials":169,"activeCount":11},[170],{"nctId":171,"briefTitle":172,"status":57,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":181},"NCT02065076","Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients",[38],"2014-09","2014-10","2014-02",38,[179,180],"Hyperkalemia","Chronic Kidney Failure",[158,182],"Lactose with carob gum",{"trials":184,"activeCount":11},[],{"intervention":182,"totalTrials":9,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":201},{"trials":188,"activeCount":11},[],{"trials":190,"activeCount":11},[],{"trials":192,"activeCount":11},[],{"trials":194,"activeCount":11},[],{"trials":196,"activeCount":11},[197],{"nctId":171,"briefTitle":172,"status":57,"phases":198,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":199,"interventions":200},[38],[179,180],[158,182],{"trials":202,"activeCount":11},[],{"intervention":204,"totalTrials":9,"cells":205},"Intravenous Lidocaine",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":227},{"trials":207,"activeCount":11},[],{"trials":209,"activeCount":11},[],{"trials":211,"activeCount":11},[],{"trials":213,"activeCount":11},[],{"trials":215,"activeCount":11},[216],{"nctId":217,"briefTitle":218,"status":70,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT01841294","NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery",[38],"2013-12","2012-01",50,[224],"Colorectal Cancer",[204,226],"Normal saline",{"trials":228,"activeCount":11},[],{"intervention":230,"totalTrials":9,"cells":231},"N2O exposure",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":249},{"trials":233,"activeCount":11},[],{"trials":235,"activeCount":11},[],{"trials":237,"activeCount":11},[],{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[242],{"nctId":243,"briefTitle":244,"status":70,"phases":245,"primaryCompletion":60,"completion":60,"start":246,"enrollment":125,"conditions":247,"interventions":248},"NCT02701478","ANI and NoL Index Variations After Standard Nociceptive Stimulus at 0, 50, 25 % of Inhaled N2O in the Anesthetic Mixture",[38],"2016-01",[15],[230],{"trials":250,"activeCount":11},[],{"intervention":252,"totalTrials":9,"cells":253},"Allopurinol",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":11},[],{"trials":257,"activeCount":11},[],{"trials":259,"activeCount":11},[],{"trials":261,"activeCount":11},[],{"trials":263,"activeCount":11},[264],{"nctId":265,"briefTitle":266,"status":57,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":222,"conditions":270,"interventions":273},"NCT02477488","Optimal Administration of Allopurinol in Dialysis Patients",[38],"2015-08","2015-06",[271,272],"Gout","Renal Insufficiency",[252],{"trials":275,"activeCount":11},[],{"intervention":277,"totalTrials":9,"cells":278},"Hydroxyethylstarch 130\u002F0.4",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":302},{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[],{"trials":284,"activeCount":11},[],{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[289],{"nctId":290,"briefTitle":291,"status":70,"phases":292,"primaryCompletion":72,"completion":72,"start":293,"enrollment":294,"conditions":295,"interventions":301},"NCT01415284","ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia",[38],"2011-10",30,[296,297,298,299,300],"Obstetric Anesthesia","Spinal Anesthesia","Hypotension","Fluid Therapy","Cesarean Section",[277],{"trials":303,"activeCount":11},[],{"intervention":78,"totalTrials":9,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":320},{"trials":307,"activeCount":11},[],{"trials":309,"activeCount":11},[],{"trials":311,"activeCount":11},[],{"trials":313,"activeCount":11},[],{"trials":315,"activeCount":11},[316],{"nctId":68,"briefTitle":69,"status":70,"phases":317,"primaryCompletion":72,"completion":72,"start":73,"enrollment":74,"conditions":318,"interventions":319},[38],[76],[78,42],{"trials":321,"activeCount":11},[],{"intervention":323,"totalTrials":9,"cells":324},"Prednisone",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":326,"activeCount":11},[],{"trials":328,"activeCount":11},[],{"trials":330,"activeCount":11},[331],{"nctId":332,"briefTitle":333,"status":334,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":345},"NCT01432080","Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant","TERMINATED",[36],"2012-12","2013-12-30","2011-09",12,[341,342,343,344],"Respiratory Tract Infections","Bronchiolitis Obliterans","Cryptogenic Organizing Pneumonia","Lung Diseases, Interstitial",[323,346,347,348],"Azithromycin","Montelukast","Symbicort",{"trials":350,"activeCount":11},[],{"trials":352,"activeCount":11},[],{"trials":354,"activeCount":11},[],{"intervention":346,"totalTrials":9,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":358,"activeCount":11},[],{"trials":360,"activeCount":11},[],{"trials":362,"activeCount":11},[363],{"nctId":332,"briefTitle":333,"status":334,"phases":364,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":365,"interventions":366},[36],[341,342,343,344],[323,346,347,348],{"trials":368,"activeCount":11},[],{"trials":370,"activeCount":11},[],{"trials":372,"activeCount":11},[],{"intervention":347,"totalTrials":9,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":376,"activeCount":11},[],{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[381],{"nctId":332,"briefTitle":333,"status":334,"phases":382,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":383,"interventions":384},[36],[341,342,343,344],[323,346,347,348],{"trials":386,"activeCount":11},[],{"trials":388,"activeCount":11},[],{"trials":390,"activeCount":11},[],{"intervention":348,"totalTrials":9,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[399],{"nctId":332,"briefTitle":333,"status":334,"phases":400,"primaryCompletion":336,"completion":337,"start":338,"enrollment":339,"conditions":401,"interventions":402},[36],[341,342,343,344],[323,346,347,348],{"trials":404,"activeCount":11},[],{"trials":406,"activeCount":11},[],{"trials":408,"activeCount":11},[],{"intervention":410,"totalTrials":9,"cells":411},"Transplantation of cord blood expanded with UM171",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":413,"activeCount":11},[],{"trials":415,"activeCount":11},[],{"trials":417,"activeCount":11},[418],{"nctId":419,"briefTitle":420,"status":57,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":151,"conditions":424,"interventions":426},"NCT02668315","Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant",[35,36],"2018-08","2015-12-16",[425],"Hematologic Malignancy",[410],{"trials":428,"activeCount":11},[],{"trials":430,"activeCount":11},[],{"trials":432,"activeCount":11},[],{"intervention":434,"totalTrials":9,"cells":435},"Rituximab",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":437,"activeCount":11},[],{"trials":439,"activeCount":11},[],{"trials":441,"activeCount":11},[442],{"nctId":443,"briefTitle":444,"status":70,"phases":445,"primaryCompletion":446,"completion":336,"start":447,"enrollment":448,"conditions":449,"interventions":451},"NCT00807196","Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma",[35,36],"2011-12","2008-09",20,[450],"Non-Hodgkins Lymphoma",[434,452,453,454],"90Y ibritumomab tiuxetan","Cyclophosphamide","Fludarabine",{"trials":456,"activeCount":11},[],{"trials":458,"activeCount":11},[],{"trials":460,"activeCount":11},[],{"intervention":452,"totalTrials":9,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":464,"activeCount":11},[],{"trials":466,"activeCount":11},[],{"trials":468,"activeCount":11},[469],{"nctId":443,"briefTitle":444,"status":70,"phases":470,"primaryCompletion":446,"completion":336,"start":447,"enrollment":448,"conditions":471,"interventions":472},[35,36],[450],[434,452,453,454],{"trials":474,"activeCount":11},[],{"trials":476,"activeCount":11},[],{"trials":478,"activeCount":11},[],{"intervention":453,"totalTrials":9,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":11},[],{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[487],{"nctId":443,"briefTitle":444,"status":70,"phases":488,"primaryCompletion":446,"completion":336,"start":447,"enrollment":448,"conditions":489,"interventions":490},[35,36],[450],[434,452,453,454],{"trials":492,"activeCount":11},[],{"trials":494,"activeCount":11},[],{"trials":496,"activeCount":11},[],{"intervention":454,"totalTrials":9,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":500,"activeCount":11},[],{"trials":502,"activeCount":11},[],{"trials":504,"activeCount":11},[505],{"nctId":443,"briefTitle":444,"status":70,"phases":506,"primaryCompletion":446,"completion":336,"start":447,"enrollment":448,"conditions":507,"interventions":508},[35,36],[450],[434,452,453,454],{"trials":510,"activeCount":11},[],{"trials":512,"activeCount":11},[],{"trials":514,"activeCount":11},[],{"intervention":516,"totalTrials":9,"cells":517},"Ginkgo biloba",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":532,"PHASE4":534,"NA":536},{"trials":519,"activeCount":11},[],{"trials":521,"activeCount":11},[],{"trials":523,"activeCount":11},[524],{"nctId":525,"briefTitle":526,"status":57,"phases":527,"primaryCompletion":176,"completion":176,"start":528,"enrollment":529,"conditions":530,"interventions":531},"NCT02376114","Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma",[36],"2011-08",19,[23],[516],{"trials":533,"activeCount":11},[],{"trials":535,"activeCount":11},[],{"trials":537,"activeCount":11},[],{"intervention":539,"totalTrials":9,"cells":540},"Bortezomib following nonmyeloablative allogeneic transplant",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":542,"activeCount":11},[],{"trials":544,"activeCount":11},[],{"trials":546,"activeCount":11},[547],{"nctId":548,"briefTitle":549,"status":57,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":125,"conditions":554,"interventions":557},"NCT02308280","Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients",[36],"2018-09-27","2023-09-27","2014-11",[555,556],"Multiple Myeloma","High-Risk Cancer",[539],{"trials":559,"activeCount":11},[],{"trials":561,"activeCount":11},[],{"trials":563,"activeCount":11},[],{"intervention":565,"totalTrials":9,"cells":566},"Imatinib mesylate",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":568,"activeCount":11},[],{"trials":570,"activeCount":11},[],{"trials":572,"activeCount":11},[573],{"nctId":574,"briefTitle":575,"status":70,"phases":576,"start":577,"enrollment":222,"conditions":578,"interventions":580},"NCT00290485","Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)",[36],"2005-08",[579],"Gastrointestinal Stromal Tumors",[565],{"trials":582,"activeCount":11},[],{"trials":584,"activeCount":11},[],{"trials":586,"activeCount":11},[],{"intervention":588,"totalTrials":9,"cells":589},"Tobramycin",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":591,"activeCount":11},[],{"trials":593,"activeCount":11},[594],{"nctId":595,"briefTitle":596,"status":57,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":604},"NCT03904836","Tobramycin Administered at the Beginning of Dialysis",[35],"2019-12-31","2019-01-31",11,[602,603],"Renal Dialysis","Renal Failure, Chronic",[588],{"trials":606,"activeCount":11},[],{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[],{"trials":612,"activeCount":11},[],{"intervention":614,"totalTrials":9,"cells":615},"ATAC Therapy",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":617,"activeCount":11},[],{"trials":619,"activeCount":11},[620],{"nctId":621,"briefTitle":622,"status":70,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":339,"conditions":626,"interventions":628},"NCT01793025","Mismatched Donor Cells to Treat Acute Myeloid Leukemia",[35],"2018-12","2012-09",[627],"Acute Myeloid Leukemia",[614],{"trials":630,"activeCount":11},[],{"trials":632,"activeCount":11},[],{"trials":634,"activeCount":11},[],{"trials":636,"activeCount":11},[],{"intervention":638,"totalTrials":19,"cells":639},"Normal Saline",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":654},{"trials":641,"activeCount":11},[],{"trials":643,"activeCount":11},[],{"trials":645,"activeCount":11},[],{"trials":647,"activeCount":11},[],{"trials":649,"activeCount":11},[650],{"nctId":217,"briefTitle":218,"status":70,"phases":651,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":652,"interventions":653},[38],[224],[204,226],{"trials":655,"activeCount":11},[656,666],{"nctId":657,"briefTitle":658,"status":57,"phases":659,"primaryCompletion":660,"completion":661,"start":174,"enrollment":662,"conditions":663,"interventions":664},"NCT02412657","Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block",[39],"2015-10","2015-11",75,[15],[665,638],"Dexamethasone",{"nctId":667,"briefTitle":668,"status":70,"phases":669,"primaryCompletion":670,"completion":671,"start":672,"enrollment":74,"conditions":673,"interventions":677},"NCT02112864","Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome",[39],"2024-12","2025-07","2014-05",[674,665,675,676],"Chronic Pain","Thoracic Surgery","Cytokines",[665,638],{"intervention":665,"totalTrials":8,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":681,"activeCount":11},[],{"trials":683,"activeCount":11},[],{"trials":685,"activeCount":11},[],{"trials":687,"activeCount":11},[],{"trials":689,"activeCount":11},[],{"trials":691,"activeCount":11},[692,696],{"nctId":657,"briefTitle":658,"status":57,"phases":693,"primaryCompletion":660,"completion":661,"start":174,"enrollment":662,"conditions":694,"interventions":695},[39],[15],[665,638],{"nctId":667,"briefTitle":668,"status":70,"phases":697,"primaryCompletion":670,"completion":671,"start":672,"enrollment":74,"conditions":698,"interventions":699},[39],[674,665,675,676],[665,638],{"intervention":701,"totalTrials":8,"cells":702},"Carbetocin",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":711,"NA":723},{"trials":704,"activeCount":11},[],{"trials":706,"activeCount":11},[],{"trials":708,"activeCount":11},[],{"trials":710,"activeCount":11},[],{"trials":712,"activeCount":11},[713],{"nctId":714,"briefTitle":715,"status":70,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":125,"conditions":719,"interventions":722},"NCT01579201","ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery",[38],"2013-03","2012-03",[720,721],"Postpartum Hemorrhage","Uterine Atony",[701],{"trials":724,"activeCount":11},[725],{"nctId":726,"briefTitle":727,"status":57,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":736},"NCT03959436","Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery",[],"2018-03-16","2017-03-29",612,[701,733,734,735],"Cesarean Section Complications","Uterotonics","Uterine Atony With Hemorrhage",[701],{"intervention":738,"totalTrials":9,"cells":739},"ranibizumab",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":11},[],{"trials":743,"activeCount":11},[],{"trials":745,"activeCount":11},[],{"trials":747,"activeCount":11},[],{"trials":749,"activeCount":11},[],{"trials":751,"activeCount":11},[752],{"nctId":753,"briefTitle":754,"status":57,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":761},"NCT00892398","Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab",[39],"2013-10","2014-03","2009-03",242,[31],[738],{"intervention":763,"totalTrials":9,"cells":764},"Tinzaparin",{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":766,"activeCount":11},[],{"trials":768,"activeCount":11},[],{"trials":770,"activeCount":11},[],{"trials":772,"activeCount":11},[],{"trials":774,"activeCount":11},[],{"trials":776,"activeCount":11},[777],{"nctId":778,"briefTitle":779,"status":57,"phases":780,"primaryCompletion":781,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":788},"NCT02719418","Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses",[],"2016-09-30","2018-12-12","2016-02-01",28,[786,787],"Renal Insufficiency, Chronic","Deep Venous Thrombosis, Protection Against",[763],{"intervention":790,"totalTrials":9,"cells":791},"Ropivacaine 0.5%",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":793,"activeCount":11},[],{"trials":795,"activeCount":11},[],{"trials":797,"activeCount":11},[],{"trials":799,"activeCount":11},[],{"trials":801,"activeCount":11},[],{"trials":803,"activeCount":11},[804],{"nctId":805,"briefTitle":806,"status":70,"phases":807,"primaryCompletion":808,"completion":808,"start":246,"enrollment":809,"conditions":810,"interventions":813},"NCT02721290","Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using Two Femoral Block Techniques",[39],"2020-12",80,[811,812],"Regional Anesthesia","Femoral Nerve Block",[790],{"intervention":815,"totalTrials":9,"cells":816},"Fentanyl and Midazolam",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":818,"activeCount":11},[],{"trials":820,"activeCount":11},[],{"trials":822,"activeCount":11},[],{"trials":824,"activeCount":11},[],{"trials":826,"activeCount":11},[],{"trials":828,"activeCount":11},[829],{"nctId":830,"briefTitle":831,"status":57,"phases":832,"primaryCompletion":833,"completion":833,"start":834,"enrollment":809,"conditions":835,"interventions":836},"NCT00723164","Premedication on Sevoflurane Induction",[39],"2005-12","2005-10",[21],[815,837],"NaCl",{"intervention":837,"totalTrials":9,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":846,"PHASE4":848,"NA":850},{"trials":841,"activeCount":11},[],{"trials":843,"activeCount":11},[],{"trials":845,"activeCount":11},[],{"trials":847,"activeCount":11},[],{"trials":849,"activeCount":11},[],{"trials":851,"activeCount":11},[852],{"nctId":830,"briefTitle":831,"status":57,"phases":853,"primaryCompletion":833,"completion":833,"start":834,"enrollment":809,"conditions":854,"interventions":855},[39],[21],[815,837],{"intervention":857,"totalTrials":9,"cells":858},"Lidocaine 1% with epinephrine 1\u002F400000",{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":860,"activeCount":11},[],{"trials":862,"activeCount":11},[],{"trials":864,"activeCount":11},[],{"trials":866,"activeCount":11},[],{"trials":868,"activeCount":11},[],{"trials":870,"activeCount":11},[871],{"nctId":872,"briefTitle":873,"status":57,"phases":874,"primaryCompletion":875,"completion":876,"start":877,"enrollment":222,"conditions":878,"interventions":881},"NCT02741232","Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery",[39],"2017-08-30","2017-09-15","2016-03",[879,880],"Nerve Block","Mastectomy",[857]]